{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-055602","form_type":"8-K","ticker":"KALV","cik":"0001348911","company_name":"KalVista Pharmaceuticals, Inc.","filed_at":"2025-03-17T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.407913+00:00","generated_at":"2026-05-24T15:19:28.586881+00:00","sec_items":["5.03"],"event_type":"other","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"KalVista changes fiscal year-end from April 30 to December 31","bullets":["Board approved change effective March 13, 2025; new fiscal year begins January 1, 2026.","Transition report on Form 10-KT will cover eight-month period May 1 through Dec 31, 2025.","During transition, a 10-Q for quarter ending July 31, 2025 will be filed, then quarters shift to Sept 30, 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-055602","json":"https://secwatch.observer/filing/0001193125-25-055602.json","markdown":"https://secwatch.observer/filing/0001193125-25-055602.md","text":"https://secwatch.observer/filing/0001193125-25-055602.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1348911/000119312525055602/0001193125-25-055602-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1348911/000119312525055602/d938905d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T15:19:28.586881+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}